Publications by authors named "John Simard"

Claim this Profile
S
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
Marion Thibaudin, Nicolas Roussot, Chloé Burlot, Antonin Schmitt, Julie Vincent, John Simard

Signal Transduct Target Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19.
Georgios Renieris, Eleni Karakike, Theologia Gkavogianni, Dionysia-Eirini Droggiti, Emmanouil Stylianakis, John Simard

J Innate Immun· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
Alice Gottlieb, Nicola E Natsis, Francisco Kerdel, Seth Forman, Edgar Gonzalez, John Simard

J Invest Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postischemic Administration of IL-1α Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke.
Luca Liberale, Nicole R Bonetti, Yustina M Puspitasari, Lena Schwarz, Alexander Akhmedov, John Simard

Circulation· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.
Razelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, Mark Saunders, Qian Wu, John Simard

Oncoimmunology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
Theodora Kanni, Maria Argyropoulou, Themistoklis Spyridopoulos, Aikaterini Pistiki, Michael Stecher, John Simard

J Invest Dermatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia.
Avanish K Varshney, Galina A Kuzmicheva, Jian Lin, Kevin M Sunley, Rodney A Bowling, John Simard

PLoS One· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point.
Jun Gong, Daniel Wu, Jeremy Chuang, Richard Tuli, John Simard

Clin Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.
Tamas Hickish, Thierry Andre, Lucjan Wyrwicz, Mark Saunders, Tomasz Sarosiek, John Simard

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
David S Hong, Filip Janku, Aung Naing, Gerald S Falchook, Sarina Piha-Paul, John Simard

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
David S Hong, David Hui, Eduardo Bruera, Filip Janku, Aung Naing, John Simard

Lancet Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.
Gabriela Senti, Bettina M Prinz Vavricka, Iris Erdmann, Mella I Diaz, Richard Markus, John J Simard

Proc Natl Acad Sci U S A· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis